Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

Native American infants, with an overall incidence and severity of adverse events (AEs) that were similar between the motavizumab and the placebo groups. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of hypersensitivity related skin rashes within two days of dosing were seen in about one percent of treated children in the motavizumab group.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pediatric patients and met its secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 , Revenues from ... , Adjusted diluted EPS from continuing operations of $1.08, ... from continuing operations of $0.92, 7% below prior year ... prior year , Full year 2014 revenues now expected ... 4% previously , Full year 2014 adjusted diluted EPS ...
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... co-promotion agreement with Illumina to facilitate the development ... for precision medicine and clinical trials. Cypher Genomics ... Illumina,s sales force, a solution including Illumina,s market ... analytics and storage, and Cypher Genomics, biomarker discovery ...
(Date:7/23/2014)... Australia , July 24, 2014 ... Melbourne , the agreement seeks to increase access ... At the AIDS 2014 conference in ... a new licensing agreement with Gilead Sciences for tenofovir alafenamide ... The licence will allow manufacturers in India ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
... ADDISON, Texas, Oct. 13, 2011 ULURU Inc. (NYSE ... a binding letter of intent with Melmed Holdings AG, a company ... Under the terms of the agreement ULURU will license the ... formed to market Altrazeal® in the European Union. In exchange for ...
... Clean Holdings, Inc. (Nasdaq: UCTT ), a leading ... equipment, flat panel, medical, energy and research industries will release ... 24, 2011 after markets close. The Company will ... and management,s outlook at 1:45 pm PDT on Monday, October ...
Cached Medicine Technology:ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3
(Date:7/24/2014)... 2014 Discount-Dress.com, an innovative company that ... occasion outfits, is doing its best to attract new ... discounted rates, up to 75% off. Recently, the company ... . Also, it has unveiled many new products for ... gorgeous lace wedding dresses, purple prom dresses and so ...
(Date:7/24/2014)... 6 Minutes to Skinny focuses on ... high gear with only a few minutes each day ... or lifestyle. This has caught the attention of HealthyandFitZone.com’s ... 6 Minutes to Skinny review shows that Craig ... understand exactly how your body responds to food and ...
(Date:7/24/2014)... South Carolina (PRWEB) July 24, 2014 A ... has found that nearly 80 percent of doctors in the ... within the previous year. , Doctors appear to be embracing ... doctors in real time, linking them to past patient histories, ... consultation with another physician. , A report from the ...
(Date:7/24/2014)... MA (PRWEB) July 24, 2014 Representatives ... will be on hand to provide educational and support ... Annual Meeting next week in Colorado Springs. , The ... some of the most renowned neurointerventional research ... solving and innovating together (with or at) symposiums, physician ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The Arm Lift, ... remove excess fat and skin from the upper arms to ... tissues in the upper arm can become lax and may ... people are embarrassed by the appearance of sagging upper arms, ... ARC Plastic Surgery Aventura is now offering brachioplasty to ...
Breaking Medicine News(10 mins):Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 2Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 3Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 2Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 3Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3
... women with diabetes during pregnancy may be an accurate, ... for unrecognized diabetes and prediabetes, according to Emory University ... women with diabetes during pregnancy may be an accurate, ... for unrecognized diabetes and prediabetes, according to Emory University ...
... Allscripts (Nasdaq: MDRX ) announced today ... and largest primary care physician groups in Southern Nevada, has ... for its physicians in three locations. , , ... has been a Misys client for several years, is upgrading ...
... says production shortfalls that limited booster shots nearly over; ... (HealthDay News) -- A children,s vaccine that,s been ... produced at levels that allow its traditional widespread use, ... Prevention announced Thursday. , Beginning in December 2007, the ...
... the breast of an adolescent girl, she often will undergo ... adolescents, and the vast majority of teenage breast lumps turn ... A recent Loyola University Health System study published in ... breast ultrasound examination might eliminate the need for biopsy in ...
... ... Dictation Tips for Physicians: Technique, technology: powerful partners for creating high quality medical transcriptions. ... Scottsdale, AZ, ... are revolutionizing how we record and store medical information, but a physician,s dictation technique ...
... German . , If you have hay ... to the nearest chemist. The drugs, on the other hand, ... animal experiments have been an essential step, yet they continue ... at offering an alternative to animal experiments," says Professor Heike ...
Cached Medicine News:Health News:Glucose challenge test is accurate and economical for diabetes and prediabetes screening 2Health News:Glucose challenge test is accurate and economical for diabetes and prediabetes screening 3Health News:Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 2Health News:Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 3Health News:Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 4Health News:Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 5Health News:Supply of Key Children's Vaccine Almost Back to Normal 2Health News:Supply of Key Children's Vaccine Almost Back to Normal 3Health News:What should a teenage girl do if she finds a lump in her breast? 2Health News:Medical Transcription Services Company MxSecure, Inc. Announces Top Ten Dictation Tips for Physicians 2Health News:Medical Transcription Services Company MxSecure, Inc. Announces Top Ten Dictation Tips for Physicians 3Health News:Artificial liver for drug tests 2
... EX.P.R.T. Release Technology essentially eliminates premature ... Unique anatomically designed tapered stent for ... 0.014 Rapid Exchange catheter with 6 ... atraumatic tip,, Radiopaque marker on catheter ...
... From top to bottom, EZ ... responsiveness, predictability, and comfort close ... Biosense Webster micro-tensioning system that ... physicians with a new level ...
... a whole blood assayed hematology control, offers ... cell differential available with the Coulter GENS, ... has 14-day open-vial stability, 105-day closed-vial stability ... high levels. The 4.0ml pierceable cap vial ...
... The Pilot® thoracolumbar pedicle screw ... deliver implants safely and quickly ... through an open procedure or ... unique screw insertion instrumentation allows ...
Medicine Products: